££......Osmetech ......Smell the Success.....££

I haven't read a single cautious word on todays update, so here's mine FWIW

To be a player in this market they know a broader range of tests are needed and soon
Much much more cash needs to be spent on R&D
'the Board intends to focus the Group's strategy on accelerating the development and expansion of the Molecular Diagnostics Division, both organically and by selective acquisitions.''
Not good enough if this old example is still the best example of revenue generation
'a customer has recently signed a two year contract with minimum consumable usage rates of approximately $75,000 per year and the Board believes that its actual usage rates may soon be in the region of $250,000 per annum.''
'Prior to the disposal, the Board had intended to fund the Group's operating costs and the development of the Molecular Diagnostics Division, AT LEAST IN PART, from the profits of the Critical Care Division''.
They have now explored all the other possibilities to raise the capital needed - unsuccessfully
It was this lack of success that lead them to sell CC, not a preferred choice (to avoid yet another placing)
Why no interest? Not a good sign

And if as it looks to me sales are taking longer than anticipated, with more R&D to come, acquisitions - cash might not last long enough
This is even more of a gamble now
Still could succeed eventually but loss making for much longer now